Athersys Revenue and Competitors

Location

$122.7M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Athersys's estimated annual revenue is currently $35M per year.(i)
  • Athersys's estimated revenue per employee is $614,035
  • Athersys's total funding is $122.7M.

Employee Data

  • Athersys has 57 Employees.(i)
  • Athersys grew their employee count by -37% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.9M6-14%N/AN/A
#2
$1.7M110%N/AN/A
#3
$0.9M6200%N/AN/A
#4
$4M2618%N/AN/A
#5
$63.6M410-9%N/AN/A
#6
$2.5M1623%N/AN/A
#7
$1.1M740%N/AN/A
#8
$12.7M82-7%N/AN/A
#9
$0.9M6200%N/AN/A
#10
$1M13-58%$193MN/A
Add Company

Athersys is a functional genomics and biopharmaceutical company engaged in the development, application and commercialization of novel gene expression tools and therapeutic products. The company’s research and development programs are focused on its two proprietary platform technologies: RAGE (Random Activation of Gene Expression™) and SMC™ (Synthetic Microchromosome™) vector system.

keywords:Biotechnology

$122.7M

Total Funding

57

Number of Employees

$35M

Revenue (est)

-37%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Athersys News

2022-03-30 - Athersys closing in on commercialization of its MultiStem stem cell ...

Athersys Inc., the biotechnology company in Cleveland, could be nearing the end of a 15-year journey to commercialize its adult stem cell...

2022-03-30 - Athersys Reports That Its Partner, HEALIOS K.K., Provides Updates ...

Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance...

2022-03-30 - Athersys to Participate in Two Upcoming Investor Conferences

Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance...

2014-04-28 - First efficacy trial of Athersys stem cell therapy yields disappointing interim results. So what now?

Cleveland-based Athersys (NASDAQ: ATHX) released the interim results today for the Phase 2 study it’s conducting with Pfizer. The randomized, double-blind, placebo-controlled study has enrolled 88 ulcerative colitis patients in the U.S., Canada and Europe who have had the disease for an average ...

2013-08-14 - Stem cell firm Athersys faces enrollment struggles with one Phase 2 study; readies to begin another

Already the company has two Phase 2 trials in progress, although one has been held up by enrollment challenges. Athersys is working with Pfizer on a trial of MultiStem in treatment-resistant ulcerative colitis patients. Last time we checked in with the company, enrollment for the study had been ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$35M5721%N/A
#2
$15M574%N/A
#3
$3.5M5743%N/A
#4
$10.5M576%N/A
#5
$13.9M5710%N/A